Basiliximab, previously identified as CHI 621 and possessing the molecular identifier 179045-86-4, represents a antibody agent utilized primarily in preventing acute dismissal following organ transplantation . This modified protein specifically binds to the interleukin-2 (IL-2) sensor , effectively hindering IL-2 pathway and subsequently reducing the patient’s reaction . Its medical purpose has been contained due to the presence of alternative immunosuppressants, although it remains a useful option in select cases where other therapies are ineffective . Further study continues to investigate its possibilities in various disease conditions .
```text
Understanding Basiliximab Antibody: Structure, Function, and Applications
The powerful monoclonal protein, basiliximab, works by specifically inhibiting T lymphocytes activation. Its design includes a pair of major chains and dual minor chains, bound by disulfide connections. Specifically, basiliximab binds to the marker 25 entity, called the interleukin 2 receptor alpha portion. This binding effectively interrupts interleukin 2 communication, a crucial process for cellular reaction. Therefore, basiliximab finds medical deployment in reducing acute refusal subsequent to body part implantation, mainly kidney and liver transplants.
```
```
CHI 621 (Basiliximab): Chemical Identity and Therapeutic Role
Basiliximab, also known as CHI 621, represents the potent monoclonal antibody targeted for the interleukin-2 receptor chain, specifically its alpha subunit . Chemically, it is this chimeric humanized protein of the IgG1 isotype , built with murine origins but designed to largely consist of human structural regions to minimize immunogenicity within patients . Its therapeutic role check here centers on preventing acute rejection occurrences in transplanted recipients, typically following heart transplantation.
- Primary Use: Preventing Rejection
- Mechanism: IL-2 Receptor Blockade
- Chemical Nature: Chimeric Monoclonal Antibody
```
Analyzing the Molecular Profile of Basiliximab Antibody
The compound identified by the CAS registry number 179045-86-4 represents a crucial element in understanding Basiliximab, a monoclonal antibody used in immunosuppression. Thorough investigation of its molecular profile requires a multifaceted analytical approach, incorporating techniques such as mass measurement, amino acid analysis , and glycan mapping . This information enables researchers to characterize the exact amino acid sequence , post-translational modifications , and glycosylation patterns that characterize Basiliximab's biological activity . Understanding these slight variations and their impact on binding to the CD25 receptor is critical for optimizing its clinical performance and designing potentially superior medicinal agents.
Anti- Basiliximab Agent: Mechanism regarding Effect and Practical Importance
Basiliximab, a cloned body, exerts its clinical effect by directly targeting the interleukin- 2 receptor (IL-2R) on T cells. Specifically, it establishes a stable interaction with the IL-2 binding site, inhibiting the binding of IL-2 and interrupting the crucial signal process for T cell expansion and stimulation. This mechanism is particularly significant in controlling early failure episodes following tissue implantation procedures. Clinical relevance stems from its power to reduce organ versus disease chance, leading in enhanced individual outcomes.
- Process of Effect
- Practical Importance
- Area of Effect
Recent Advances in Basiliximab Research: Focusing on CHI 621 and 179045-86-4
Current research into basiliximab treatment is observing notable progress , particularly with novel focus on two intriguing compounds: CHI 621 and 179045-86-4. CHI 621, a altered basiliximab agent, demonstrates enhanced specificity for the CD25 receptor, potentially minimizing off-target effects and optimizing its therapeutic efficacy . Similarly, 179045-86-4, a analogous substance , is under assessment for its distinct mechanism of action on immune cell function and its potential to complement existing basiliximab-based protocols. These ongoing programs signify a change towards more refined immunosuppressive interventions for transplantation and immune-mediated conditions .